Legend Biotech Corporation (NASDAQ: LEGN) announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for LB2501, an off‑the‑shelf, single‑infusion in vivo CAR‑T therapeutic designed to generate CD19/CD20 dual‑target CAR‑T cells directly within patients for the treatment of relapsed or refractory B‑cell malignancies, including B‑cell non‑Hodgkin lymphoma (B‑NHL) – with the authorized U.S. Phase I/II study proceeding without the need for lymphodepleting chemotherapy.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | U.S. Food and Drug Administration (FDA) |
| Authorization Type | Investigational New Drug (IND) application approved |
| Product | LB2501 – off‑the‑shelf, single‑infusion in vivo CAR‑T |
| Indication | Relapsed or refractory B‑cell malignancies, including B‑NHL |
| Authorized Study | U.S. Phase I/II clinical trial |
| Key Design Feature | Evaluated without lymphodepleting chemotherapy |
| IND Clearance Date | 15 Oct 2026 |
| Next Steps | Initiate Phase I/II evaluation of safety, tolerability, pharmacokinetics, and preliminary efficacy; timeline not disclosed |
Drug Profile & Mechanism of Action
- Modality: In vivo CAR‑T – an off‑the‑shelf, single‑infusion therapeutic engineered to generate CAR‑T cells directly inside the patient’s body, bypassing the ex vivo cell manufacturing required by conventional autologous CAR‑T therapies.
- Target: Dual‑targeting CD19 and CD20 on malignant B cells – a design intended to broaden antigen coverage and mitigate antigen‑escape relapse seen with single‑target CD19 CAR‑T products.
- Conditioning Innovation: Being evaluated without lymphodepleting chemotherapy, addressing a major source of toxicity, inpatient burden, and treatment delay in current CAR‑T regimens.
- Access Advantage: As an off‑the‑shelf product, LB2501 has the potential to eliminate vein‑to‑vein wait times and per‑patient manufacturing slots – key access constraints in relapsed/refractory B‑NHL.
- Pipeline Position: Extends Legend Biotech’s CAR‑T franchise beyond its commercialized ex vivo cell therapy expertise into next‑generation in vivo engineering.
Planned Clinical Evaluation – Phase I/II Study
| Component | Detail |
|---|---|
| Study Phase | Phase I/II (U.S.) |
| Population | Relapsed or refractory B‑cell malignancies, including B‑NHL |
| Primary Assessments | Safety, tolerability, pharmacokinetics |
| Efficacy Assessment | Preliminary efficacy |
| Lymphodepletion | Not required per study design |
| Data Status | No clinical data disclosed to date |
Market Impact & Outlook
- In Vivo CAR‑T Race: LB2501’s IND clearance places Legend Biotech among the developers pushing in vivo CAR‑T – one of the most closely watched next‑generation modalities – into the clinic for hematologic malignancies.
- Differentiated Regimen: The combination of CD19/CD20 dual targeting and a chemotherapy‑free approach could improve the benefit‑risk profile versus both approved autologous CAR‑T products and ex vivo allogeneic candidates, if validated in the Phase I/II study.
- Franchise Context: Legend, established in CAR‑T through its commercial B‑cell maturation antigen (BCMA) franchise in multiple myeloma, is diversifying into B‑NHL and in vivo engineering with LB2501.
- Milestones Ahead: Key catalysts include first‑patient dosing and initial safety/tolerability readouts; timing, sites, and enrollment targets were not disclosed.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the clinical development, regulatory pathway, and commercial potential of LB2501. IND clearance authorizes early‑stage study only; the candidate carries substantial risk of failure, and actual results may differ due to trial outcomes, safety findings, and competitive dynamics. This summary is for informational purposes only and does not constitute investment advice.-Fineline Info & Tech
